Few drug classes have reshaped clinical practice as rapidly as GLP-1 receptor agonists (GLP-1 RAs) — semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and liraglutide (Victoza/Saxenda) now headline conversations about obesity medicine, cardiovascular prevention, and metabolic syndrome management. But what does the evidence actually show, and what do clinicians need to know beyond the marketing?
Mechanism: More Than Just Appetite Suppression
GLP-1 RAs work through multiple synergistic mechanisms: GLP-1 receptor stimulation in the pancreas potentiates glucose-dependent insulin secretion and suppresses glucagon; in the hypothalamus and brainstem, GLP-1 signaling reduces appetite and food reward; gastric emptying is slowed, prolonging satiety; and emerging data show direct effects on adipose tissue metabolism and inflammation. Tirzepatide adds GIP receptor agonism — a dual-incretin approach that produces superior weight loss versus semaglutide in head-to-head trials (SURMOUNT-5: −20.2% vs −13.7% body weight at 72 weeks).
Weight Loss Outcomes: The SCALE and STEP Trials
STEP 1 (semaglutide 2.4mg weekly, n=1961): 14.9% mean weight reduction versus 2.4% placebo at 68 weeks, with 86% achieving ≥5% weight loss. SURMOUNT-1 (tirzepatide, n=2539): 20.9% mean weight loss at highest dose versus 3.1% placebo — results approaching bariatric surgery outcomes for some patients. The SELECT trial (semaglutide in cardiovascular disease): 20% reduction in MACE in patients with obesity and established CVD — a paradigm shift positioning GLP-1 RAs as cardiovascular preventive agents beyond glycemic control.
What Providers Need to Know: Risks and Monitoring
GI side effects (nausea, vomiting, diarrhea) affect 30–50% of patients, are dose-dependent, and typically improve over 4–8 weeks with slow dose titration. Pancreatitis risk: boxed warning but absolute risk appears low (0.1–0.3% in trials). Thyroid C-cell tumors: contraindicated in personal/family history of medullary thyroid carcinoma or MEN2 (based on rodent data — human risk unclear but taken seriously). Muscle mass loss with rapid weight reduction: emerging concern, particularly in older adults — resistance training and adequate protein intake are important co-interventions. Drug shortages and cost (>$1000/month without coverage) remain major access barriers. For facilities managing diabetic patients on GLP-1 therapy, our diagnostic equipment section includes continuous glucose monitoring supplies and our wound care supplies support diabetic ulcer management in this population.
